Retina/Vitreous News

PARK CITY, Utah — Stage one of the phase 3 DIAMOND trial of OCS-01, a high-concentration dexamethasone eye drop for diabetic macular edema, showed promising safety and efficacy outcomes. Stage two of the trial is underway.

A review of currently available data suggests that there is little or no difference in efficacy and safety between anti-VEGF biosimilars approved for neovascular age-related macular degeneration and their reference products.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carlos Quezada-Ruiz, MD, FASRS, of Genentech/Roche shares an update on Susvimo and the port delivery platform.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses presentations from the ARVO annual meeting on real-world use of faricimab and the use of pegcetacoplan in the treatment of geographic atrophy.

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Doug Faunce, PhD, reviews AbbVie’s ongoing efforts in the eye care field.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Charles Semba, MD, chief medical officer of Eluminex Biosciences, discusses a trispecific antibody for refractory diabetic macular edema.

The current prior authorization process required for anti-VEGF medications leads to treatment delays, increased health care costs due to administrative burdens and potentially worse visual outcomes.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Adam Turpcu, PhD, of Adverum Biotechnologies discusses Ixo-vec for neovascular age-related macular degeneration.

Genentech is set to reintroduce Susvimo for patients with wet age-related macular degeneration nearly 2 years after it voluntarily recalled the ocular implant, according to a press release.